Beconase
information and resources from the National Cancer Institute
Beconase
(Other name for: beclomethasone dipropionate)Benefin
(Other name for: shark cartilage)Beconase
(Other name for: beclomethasone dipropionate)
|
|
|
|
news articles
Rigel Announces Disappointing Results from Phase II Study of R112 ... Dec 1, 2005
PR Newswire (press release), The randomized, double-blind study compared R112 and Beconase AQ(R) (beclomethasone) nasal spray to placebo, over a 7-day period. ...
Poor drug trial trips Rigel Pharma Dec 1, 2005
MarketWatch The same trial also showed another allergy drug, Beconase AQ, was effective when compared to a placebo in treating allergy symptoms. ...
Rigel allergy drug fades in Phase 2 trial Dec 1, 2005
United Press International Rigel said its potential treatment, which was pitted against GlaxoSmithKline's Beconase nasal spray, failed to show a statistically significant difference from ...
About this Author Dec 1, 2005
Corante They ran about 400 patients through a seven-day course of either their inhaled drug, a placebo, or Beconase, an inhaled steroid from GSK. ...
UPDATE 1-Rigel hay fever treatment fails in clinical trial Dec 1, 2005
Reuters In the phase II trial, a randomized, double-blind study over seven days, a rival treatment, Beconase AQ nasal spray, demonstrated superior results relative to ...
UPDATE 2-Rigel hay fever treatment fails in clinical trial Dec 1, 2005
Reuters Phase II trial. But a rival treatment, Beconase AQ nasal spray, proved superior to placebo in the seven-day study. Rigel Chief Executive ...
Rigel down on disappointing allergy drug study Dec 1, 2005
San Jose Mercury News, ...symptoms. In the same seven-day study, the GlaxoSmithKline PLC Beconase nasal spray was superior to placebo treatment, Rigel said. ...
Rigel's Failure Could Cause Jitters For Pfizer Dec 1, 2005
Forbes ..."In light of the fact that allergen exposure and the performance of the active control (Beconase, an intranasal steroid) was as expected, we speculate that the ...
Drugs stocks climb while Rigel dives on drug data Dec 1, 2005
Investor's Business Daily (subscription) The same trial showed that another drug, Beconase AQ, was effective. ... Rigel's bad news appeared to give a boost to GlaxoSmithKline, which markets Beconase AQ. ...
Poor drug trial trips Rigel Pharma Dec 1, 2005
MarketWatch ...allergy symptoms. , , ) , over a 7-day period. Beconase AQ was found to be superior to the placebo treatment in the trial. "We are ...
Health Stocks in Motion Dec 1, 2005
TheStreet.com ...the earlier phase II 'Park' study of R112 demonstrated a statistically significant reduction in the symptoms associated with the allergies." Beconase AQ, a ...
Rigel Announces Disappointing Results from Phase II Study of R112 ... Dec 1, 2005
PR Newswire (press release), The randomized, double-blind study compared R112 and Beconase AQ(R) (beclomethasone) nasal spray to placebo, over a 7-day period. ...
Poor drug trial trips Rigel Pharma Dec 1, 2005
MarketWatch The same trial also showed another allergy drug, Beconase AQ, was effective when compared to a placebo in treating allergy symptoms. ...
Rigel allergy drug fades in Phase 2 trial Dec 1, 2005
United Press International Rigel said its potential treatment, which was pitted against GlaxoSmithKline's Beconase nasal spray, failed to show a statistically significant difference from ...
About this Author Dec 1, 2005
Corante They ran about 400 patients through a seven-day course of either their inhaled drug, a placebo, or Beconase, an inhaled steroid from GSK. ...
UPDATE 1-Rigel hay fever treatment fails in clinical trial Dec 1, 2005
Reuters In the phase II trial, a randomized, double-blind study over seven days, a rival treatment, Beconase AQ nasal spray, demonstrated superior results relative to ...
UPDATE 2-Rigel hay fever treatment fails in clinical trial Dec 1, 2005
Reuters Phase II trial. But a rival treatment, Beconase AQ nasal spray, proved superior to placebo in the seven-day study. Rigel Chief Executive ...
Rigel down on disappointing allergy drug study Dec 1, 2005
San Jose Mercury News, ...symptoms. In the same seven-day study, the GlaxoSmithKline PLC Beconase nasal spray was superior to placebo treatment, Rigel said. ...
Rigel's Failure Could Cause Jitters For Pfizer Dec 1, 2005
Forbes ..."In light of the fact that allergen exposure and the performance of the active control (Beconase, an intranasal steroid) was as expected, we speculate that the ...
Drugs stocks climb while Rigel dives on drug data Dec 1, 2005
Investor's Business Daily (subscription) The same trial showed that another drug, Beconase AQ, was effective. ... Rigel's bad news appeared to give a boost to GlaxoSmithKline, which markets Beconase AQ. ...
Poor drug trial trips Rigel Pharma Dec 1, 2005
MarketWatch ...allergy symptoms. , , ) , over a 7-day period. Beconase AQ was found to be superior to the placebo treatment in the trial. "We are ...
Health Stocks in Motion Dec 1, 2005
TheStreet.com ...the earlier phase II 'Park' study of R112 demonstrated a statistically significant reduction in the symptoms associated with the allergies." Beconase AQ, a ...
|
|
